Clinical DevelopmentArriVent's reported clinical progress with firmonernib, including initial clinical results and the selection of a development candidate, could signal future growth prospects.
Financial ValuationA discounted cash flow-based valuation suggests ArriVent stock has a significant upside, with a potential price target of $25 per share.
Market PotentialFurmonertinib's potential to address a broad range of EGFR mutations and its possibility for premium pricing positions it as a significant contributor to future annual sales.